TG Therapeutics, Inc.
As of Oct 22, 2026, TG Therapeutics is in Stage 2, the uptrend phase, now in week 25 (since Apr 29, 2026). It closed at $53.16, 10.0% below its 52-week high and above its 200-day average, which is rising.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United State… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is TGTX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
TGTX among Biotechnology89th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …89 | TGTX | Stage 2 · wk 25 | 86 | −5.1% |
TG Therapeutics: quick answers
What stage is TG Therapeutics in?
As of Oct 22, 2026, TG Therapeutics (TGTX) is in Stage 2, the uptrend phase. It entered Stage 2 on Apr 29, 2026 and is in week 25. What the four stages mean
Is TG Therapeutics in an uptrend?
Yes. TG Therapeutics is in a Stage 2 uptrend. It trades 23.7% above its 200-day average, which is rising.
How far is TG Therapeutics from its 52-week high?
TG Therapeutics closed at $53.16 on Oct 22, 2026, 10.0% below its 52-week high of $59.06. Its 52-week low is $26.94.
How has TG Therapeutics performed over the past year?
As of Oct 22, 2026, TG Therapeutics is up 50.9% over the past year and up 81.6% so far in 2026.
Which sector and industry is TG Therapeutics in?
TG Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.